StreetInsider.com News Articles

Lake Street Starts Beyond Air (XAIR) at Buy

Tue, 01 Sep 2026 08:06:29 -0400

Lake Street analyst Frank Takkinen initiates coverage on Beyond Air (NASDAQ: XAIR) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Beyond Air click here. For more ratings news on Beyond Air click here.

Shares of Beyond Air closed at $3.97 yesterday.

FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease

Mon, 31 Aug 2026 08:04:08 -0400

Beyond Air, Inc. (NASDAQ: XAIR) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its LungFit GO device for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD).

The designation applies to a portable device designed to deliver high-dose intermittent inhaled nitric oxide therapy in a home setting. NTM-PD is a rare chronic bacterial lung infection that often requires prolonged multidrug antibiotic regimens lasting up to two years.

The FDA grants Breakthrough Device Designation when a device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions, with the aim of speeding up development

FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease

Mon, 31 Aug 2026 08:04:08 -0400

FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease

Mon, 31 Aug 2026 08:04:08 -0400

FDA grants Beyond Air's LungFit GO breakthrough device status for lung disease

Mon, 31 Aug 2026 08:04:08 -0400

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

Beyond Air, Inc. (NASDAQ: XAIR) has entered into a definitive agreement to sell its stake in NeuroNOS Israel Ltd. to UNIVO Pharmaceutical Industries Ltd. (TASE: UNVO), a publicly traded Israeli company, according to a press release issued Aug. 25, 2026.

Under the terms of the deal, UNIVO will acquire NeuroNOS Limited, a wholly owned Irish subsidiary of Beyond Air that holds approximately 58% of NeuroNOS's issued share capital on a fully diluted basis, representing 5,000,000 ordinary shares.

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air to sell NeuroNOS stake to Univo for equity and milestones

Tue, 25 Aug 2026 07:01:17 -0400

In exchange, Beyond Air will receive UNIVO ordinary shares representing 19.99% of UNIVO's issued and outstanding share capital, along with warrants to purchase additional UNIVO

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

Tue, 25 Aug 2026 07:00:00 -0400

Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing